The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer

Pancreas

Volumn 20, Issue 4, 2000, Pages 378-381

  Tanaka, Noriaki ^a   Okada, Shuichi ^a   Ueno, Hideki ^a   Okusaka, Takuji ^a   Ikeda, Masahumi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

CA 19 9; Chronic pancreatitis; Diagnosis; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MALE; PANCREAS CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CHRONIC DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATITIS; TIME FACTORS;

EID: 0034062142     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200005000-00007     Document Type: Article

References (18)

1. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastoroenterology 1986;90:343-9.
2. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar W. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-8.
3. Ishii H, Okada S, Sato T, et al. CA19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44:279-83.
4. Okusaka T, Okada S, Sato T, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 1998;45:867-72.
5. Stein WM. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
6. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988;33: 1223-5.
7. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92:61-7.
8. Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer 1996;73:372-6.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
10. Ekbom A, McLaughlin JK, Karlson BM, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994;86:625-7.
11. Ormson MJ, Charboneau JW, Stephens DH. Sonography in patients with a possible pancreatic mass shown on CT. AJR 1987; 148:551-5.
12. Ferrucci JT Jr, Wittenberg J, Black EB, Kirkpatrick RH, Hall DA. Computed body tomography in chronic pancreatitis. Radiology 1979;130:175-82.
13. Homma T, Harada H, Koizumi M. Diagnostic criteria for chronic pancreatitis by Japanese Pancreas Society. Pancreas 1997;15: 14-5.
14. Sobin LH, Wittekind Ch, eds. UICC-TNM classification of malignant tumors, 5th ed. New York: John Wiley, 1997.
15. Niederau C, Grendel HJ. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992;7:66-86.
16. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988;62:2287-290.
17. Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6.
18. Cerwenka H, Aigner R, Quehenberger F, et al. Preoperative differential diagnosis of benign and malignant pancreatic lesions-the value of pancreatic secretory trypsin inhibitor and procarboxypeptidase B, CA19-9, and CEA. Hepatogastroenterology 1997;44: 1117-21.